lamivudine and zidovudine

FDA Drug Profile — COMBIVIR, LAMIVUDINE AND ZIDOVUDINE

lamivudine and zidovudine is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand names including COMBIVIR, LAMIVUDINE AND ZIDOVUDINE. Available dosage form: tablet, film coated.

Drug Details

Generic Name
lamivudine and zidovudine
Brand Names
COMBIVIR, LAMIVUDINE AND ZIDOVUDINE
Application Number
NDA020857
Sponsor
ViiV Healthcare Company
NDC Codes
2
Dosage Forms
TABLET, FILM COATED
Routes
ORAL
Active Ingredients
LAMIVUDINE, ZIDOVUDINE

Indications and Usage

1 INDICATIONS AND USAGE Lamivudine and zidovudine tablets a combination of 2 nucleoside analogues, are indicated in combination with other antiretrovirals for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Lamivudine and zidovudine tablets, a combination of 2 nucleoside analogue reverse transcriptase inibitors, are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.